Status | Study |
RECRUITING |
Study Name: A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine Condition: Herpes Zoster Date: 2023-02-09 Interventions: 0.5 mL per dose, containing a total of 50 �g recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant. |
RECRUITING |
Study Name: A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine Condition: Herpes Zoster Date: 2023-02-09 Interventions: 0.5 mL per dose, containing a total of 50 �g recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant. |
ACTIVE_NOT_RECRUITING |
Study Name: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age Condition: Herpes Zoster Date: 2023-01-18 Interventions: Sterile liquid dispersion for injection |
Active, not recruiting |
Study Name: Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above Condition: Herpes Zoster Date: 2022-11-16 Interventions: Interventional |
RECRUITING |
Study Name: Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population Condition: Herpes Zoster Date: 2022-10-08 Interventions: Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster.It is supplied as lyophilized recombinant VZV surface gE antigen f |
Completed |
Study Name: A Clinical Trial of PEGIFN?1b in Chinese Healthy Adults Condition: Herpes Zoster Date: 2020-06-16 Interventions: Interventional |
Recruiting |
Study Name: Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Condition: Herpes Zoster Date: 2017-01-01 Interventions: Biological: Zostavax vaccine After the screening, the eligible patients who provided the informed consen |
Active, not recruiting |
Study Name: Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age Condition: Herpes Zoster Date: 2016-11-29 Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) 2 doses administered by |
Completed |
Study Name: Herpes Zoster Prevalence in Frailty Consultations Condition: Herpes Zoster Date: 2016-07-01 Interventions: Other: Medical Questionary The medical questionary will co |
Active, not recruiting |
Study Name: Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older Condition: Herpes Zoster Date: 2016-04-07 Interventions: Biological: Herpes Zoster Vaccine GSK1437173A Intramuscular injection |